Lirilumab - CAS 1000676-41-4

Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN) .

Virus Protease

Microbiology/Virology

1000631

0.984

-20°C

Ice Packs

Inhibitory Antibodies